1. Home
  2. SLN vs NKSH Comparison

SLN vs NKSH Comparison

Compare SLN & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$13.87

Market Cap

300.9M

Sector

Health Care

ML Signal

HOLD

Logo National Bankshares Inc.

NKSH

National Bankshares Inc.

HOLD

Current Price

$42.43

Market Cap

265.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
NKSH
Founded
1994
1891
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
300.9M
265.7M
IPO Year
2010
1995

Fundamental Metrics

Financial Performance
Metric
SLN
NKSH
Price
$13.87
$42.43
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$42.60
N/A
AVG Volume (30 Days)
1.1M
34.6K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
4.22%
EPS Growth
N/A
100.81
EPS
N/A
0.78
Revenue
$559,000.00
$8,176,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$54.15
Revenue Growth
N/A
9.39
52 Week Low
$4.19
$27.00
52 Week High
$17.58
$42.49

Technical Indicators

Market Signals
Indicator
SLN
NKSH
Relative Strength Index (RSI) 69.56 68.14
Support Level $5.28 $34.46
Resistance Level N/A $42.49
Average True Range (ATR) 1.12 1.63
MACD 0.29 0.22
Stochastic Oscillator 58.02 89.93

Price Performance

Historical Comparison
SLN
NKSH

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.

Share on Social Networks: